Cargando…
REDUCED COVID-19 VACCINE RESPONSE IN PATIENT TREATED WITH DUPILUMAB FOR IGG4 RELATED DISEASE.
INTRODUCTION: Dupilumab is a novel anti-interleukin-4 (IL-4) receptor-α monoclonal antibody that targets the signaling pathways of IL-4 and IL-13. There there has been limited data about adequate humoral immune response after vaccination to SARS-CoV-2 in patients on dupilumab. CASE DESCRIPTION: We p...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646421/ http://dx.doi.org/10.1016/j.anai.2022.08.973 |